Efficacy and safety of cinnamon in type 2 diabetes mellitus and pre-diabetes patients: A meta-analysis and meta-regression

• Published in: Diabetes research and clinical practice Vol. 156; p. 107815
• Main Authors: Deyno, Serawit, Eneyew, Kassahun, Seyfe, Sisay, Tuyiringire, Naasson, Peter, Emanuel L., Muluye, Rekik Ashebir, Tolo, Casim Umba, Ogwang, Patrick Engeu
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.10.2019
• Subjects: Blood sugar level; Cinnamomum zeylanicum - chemistry; Diabetes mellitus; Diabetes Mellitus, Type 2 - drug therapy; Efficacy; Herbal therapy; Humans; Prediabetic State - drug therapy; Systematic review; T2DM; AST; Herbal therapy; Blood sugar level; LDL-C; Diabetes mellitus; Efficacy; Systematic review; ALT; DM; FBG; TC; WMD; HDL-C; TG; RBG; Hb1Ac
• ISSN: 0168-8227; 1872-8227
• DOI: 10.1016/j.diabres.2019.107815

Cinnamon has been used as a dietary component and in the management of diabetes mellitus. This study systematically reviewed and synthesized evidence on the efficacy of cinnamon for the treatment of type 2 diabetes mellitus (T2DM) and pre-diabetes patients. Databases of Web of Sciences, the Cochrane library, PubMed, CINAHL and SCOPUS were searched. Stata version 13 (College Station, Texas 77845 USA) and RevMan var. 5.3 software were used for meta-analysis. Heterogeneity was assessed using Chi-square and I2 tests. Sixteen randomized controlled studies were included in the meta-analysis. Cinnamon significantly reduced fasting blood glucose (FBG) and homeostatic model assessment for insulin resistance (HOMA-IR) level compared to placebo with weighted mean difference (WMD) of −0.545 (95% CI: −0.910, −0.18) mmol/L, I2 = 83.6% and −0.714(−1.388, −0.04), I2 = 84.4% respectively. There was no significant change in weighted mean difference of glycosylated hemoglobin A1C (HbA1c) % and lipid profiles (mmol/L). Meta-regression did not show any factor significantly affecting the treatment response. Cinnamon reduced FBG and HOMA-IR, level in T2DM and pre-diabetes patients compared to placebo. High heterogeneity observed among included studies warrants further clinical trials after standardization of cinnamon formulation.